A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
Work
Year: 2010
Type: article
Source: Investigational New Drugs
Institutions University of Michigan, Hebron University, Medizinische Hochschule Hannover, PharmaMar (Spain)
Cites: 11
Cited by: 22
Related to: 10
FWCI: 0.666
Citation percentile (by year/subfield): 73.52
Subfield: Molecular Biology
Domain: Life Sciences
Sustainable Development Goal Life below water
Open Access status: closed